These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Clinical experiences with carteolol in patients with essential hypertension]. Viehmann P Arzneimittelforschung; 1983; 33(2a):322-5. PubMed ID: 6340701 [TBL] [Abstract][Full Text] [Related]
5. Step II treatment with labetalol for essential hypertension. Bloomfield SS; Lucas CP; Gantt CL; Poland MP; Medakovic M Am J Med; 1983 Oct; 75(4A):81-6. PubMed ID: 6356902 [TBL] [Abstract][Full Text] [Related]
6. A controlled study of the antihypertensive effect of carteolol, a new beta-adrenergic receptor blocking drug, in combination with hydrochlorothiazide and amiloride. Tarkiainen A; Saraste K; Seppälä T; Gordin A; Auvinen J Eur J Clin Pharmacol; 1981 Mar; 19(4):239-44. PubMed ID: 6116605 [No Abstract] [Full Text] [Related]
7. [Hypotensive effect of carteolol in patients with essential hypertension]. Beythien RD Arzneimittelforschung; 1983; 33(2a):330-3. PubMed ID: 6682325 [TBL] [Abstract][Full Text] [Related]
8. Comparison of nitrendipine combined with low-dose hydrochlorothiazide to hydrochlorothiazide alone in mild to moderate essential hypertension. Schoenberger JA; Glasser SP; Ram CV; McMahon SG; Vanov SK; Leibowitz DA J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1105-8. PubMed ID: 6085376 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Germino FW Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225 [TBL] [Abstract][Full Text] [Related]
11. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH). Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD; Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators. Guthrie R; Reggi DR; Plesher MM; Saini RK; Battikha JP Am J Hypertens; 1996 Apr; 9(4 Pt 1):306-11. PubMed ID: 8722432 [TBL] [Abstract][Full Text] [Related]
13. Carteolol treatment of essential hypertension: a long-term study of safety and efficacy. Luther RR; Maurath CJ; Klepper MJ; Peckinpaugh RO; Ringham GL J Int Med Res; 1986; 14(4):175-84. PubMed ID: 3758467 [TBL] [Abstract][Full Text] [Related]
14. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. Widmann L; van der Does R; Hörrmann M; Machwirth M Eur J Clin Pharmacol; 1990; 38 Suppl 2():S143-6. PubMed ID: 1974505 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension. Ollivier JP; Durier P; Bussiere JL; Gayet JL Eur J Clin Pharmacol; 1990; 38 Suppl 2():S164-6. PubMed ID: 1974509 [TBL] [Abstract][Full Text] [Related]
16. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Lacourcière Y; Neutel JM; Schumacher H Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of essential hypertension with the beta-receptor antagonist carteolol. A multicenter study]. Rosprich G; Sölter H Arzneimittelforschung; 1983; 33(2a):334-9. PubMed ID: 6682326 [No Abstract] [Full Text] [Related]
18. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Luque Otero M; Martell Claros N; Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479 [TBL] [Abstract][Full Text] [Related]
19. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerance of sustained-release diltiazem 300 mg and a diuretic in the elderly. Djian J; Roy M; Forette B; Lekieffre J; Luccioni R J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S51-5. PubMed ID: 1706015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]